Company intelligence
BIOGENERA SpA
Unisciti a Biogenera. Investi in un futuro migliore”: https://www.crowdfundme.it/projects/biogenera-2/?pass=Biogenera2
About BIOGENERA SpA
BIOGENERA SpA is a company operating in the biotechnology pharmaceutical sector, specialising in the research and development of new DNA-based patient-specific biotechnological medicines for the treatment of serious pathologies. Founded in 2008, with its headquarters in Bologna, BIOGENERA SpA has a multidisciplinary team of researchers and is supported by numerous University partnerships ( in particular, the University of Bologna) and other companies of the pharmaceutical sector. Mission To create new treatments for diseases as yet considered incurable, focusing specifically on paediatric tumors. Thanks to the exclusive MyGeneraTM platform, BIOGENERA is capable of rapidly identifying and developing new patient-specific medicines aimed at every therapeutic target made up of single mutated genes, considered causative for a pathology. MyGeneraTM permits, with a unique and innovative approach, the identification and development of gene-specific molecules for absolutely patient-specific DNA-cures. BIOGENERA SpA è una società che opera nel settore delle biotecnologie farmaceutiche, specializzata nella ricerca e di sviluppo di nuovi farmaci biotecnologici personalizzati a DNA per il trattamento di patologie gravi. Costituita nel 2008, con sede a Bologna, BIOGENERA SpA conta su un team multidisciplinare di ricercatori italiani e si avvale di numerose partnerships con Università (in particolare con l’Università di Bologna) e ditte del settore farmaceutico. La nostra mission è generare nuovi trattamenti per malattie ad oggi incurabili, con un focus specifico sui tumori pediatrici. Grazie all’esclusiva piattaforma MyGeneraTM, BIOGENERA è in grado di identificare e sviluppare rapidamente nuovi farmaci specifici mirati ad ogni bersaglio terapeutico costituito da un singolo gene mutato considerato causale per una patologia.
Verified activity
Signals from BIOGENERA SpA
5 published signals
Presence & Recognition
BIOGENERA SpA is hosting a special webinar on the collection 2026 and Q&A on 18.00
Reported by BIOGENERA SpA
Capital & Finance
BIOGENERA SpA reached and exceeded €500,000 in investment on CrowdFundMe through over 100 new shareholders.
Reported by BIOGENERA SpA
Research & Knowledge
BIOGENERA SpA is working on a precision therapy targeting the gene MYCN for pediatric aggressive tumors such as neuroblastoma and rabbid myeloma, with the BGA002 program approaching clinical trials in Padova in 2027.
Reported by BIOGENERA SpA
Capital & Finance
BIOGENERA SpA is currently active in equity crowdfunding on CrowdFundMe to raise €2.5 million, with already collected funds exceeding €460,000.
Reported by BIOGENERA SpA
Presence & Recognition
BIOGENERA SpA is hosting a special web conference on 7 September at 18:00 on CrowdFundMe to discuss the equity crowdfunding campaign, BGA002, and future prospects.
Reported by BIOGENERA SpA